Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
ST2001
/
Segue Therap
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|
|||||||||
ST2001
/
Segue Therap
Journal:
Adenosine AR/AR Antagonists Enabling Additional HR Antagonism for the Treatment of Parkinson's Disease.
(Pubmed Central) - Aug 25, 2021
l-DOPA-induced dyskinesia was improved after administration of compound 4 (1 mg kg, i.p. rats). Compound 12 (2 mg kg, p.o. mice) increased wakefulness representing novel pharmacological tools for PD therapy.